Literature DB >> 20332000

Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Abir T El-Alfy1, Kelly Ivey, Keisha Robinson, Safwat Ahmed, Mohamed Radwan, Desmond Slade, Ikhlas Khan, Mahmoud ElSohly, Samir Ross.   

Abstract

The antidepressant action of cannabis as well as the interaction between antidepressants and the endocannabinoid system has been reported. This study was conducted to assess the antidepressant-like activity of Delta(9)-THC and other cannabinoids. Cannabinoids were initially evaluated in the mouse tetrad assay to determine doses that do not induce hypothermia or catalepsy. The automated mouse forced swim (FST) and tail suspension (TST) tests were used to determine antidepressant action. At doses lacking hypothermic and cataleptic effects (1.25, 2.5, and 5 mg/kg, i.p.), both Delta(9)-THC and Delta(8)-THC showed a U-shaped dose response with only Delta(9)-THC showing significant antidepressant-like effects at 2.5 mg/kg (p<0.05) in the FST. The cannabinoids cannabigerol (CBG) and cannabinol (CBN) did not produce antidepressant-like actions up to 80 mg/kg in the mouse FST, while cannabichromene (CBC) and cannabidiol (CBD) exhibited significant effect at 20 and 200mg/kg, respectively (p<0.01). The antidepressant-like action of Delta(9)-THC and CBC was further confirmed in the TST. Delta(9)-THC exhibited the same U-shaped dose response with significant antidepressant-like action at 2.5 mg/kg (p<0.05) while CBC resulted in a significant dose-dependent decrease in immobility at 40 and 80 mg/kg doses (p<0.01). Results of this study show that Delta(9)-THC and other cannabinoids exert antidepressant-like actions, and thus may contribute to the overall mood-elevating properties of cannabis. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332000      PMCID: PMC2866040          DOI: 10.1016/j.pbb.2010.03.004

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  67 in total

1.  Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents.

Authors:  John F Cryan; Daniel Hoyer; Athina Markou
Journal:  Biol Psychiatry       Date:  2003-07-01       Impact factor: 13.382

2.  The tail suspension test: ethical considerations.

Authors:  B Thierry; L Stéru; P Simon; R D Porsolt
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

4.  Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.

Authors:  G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

5.  Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test.

Authors:  James J Crowley; Julie A Blendy; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test.

Authors:  Caroline E Renard; Eric Dailly; Denis J P David; Martine Hascoet; Michel Bourin
Journal:  Fundam Clin Pharmacol       Date:  2003-08       Impact factor: 2.748

7.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

8.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Cannabinoid ester constituents from high-potency Cannabis sativa.

Authors:  Safwat A Ahmed; Samir A Ross; Desmond Slade; Mohamed M Radwan; Fazila Zulfiqar; Rae R Matsumoto; Yan-Tong Xu; Eddy Viard; Robert C Speth; Vardan T Karamyan; M A ElSohly
Journal:  J Nat Prod       Date:  2008-02-28       Impact factor: 4.050

10.  Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis.

Authors:  Inge van Rossum; Maarten Boomsma; Diederik Tenback; Catherine Reed; Jim van Os
Journal:  J Nerv Ment Dis       Date:  2009-01       Impact factor: 2.254

View more
  57 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

3.  The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System.

Authors:  Anthony L Berger; Angela M Henricks; Janelle M Lugo; Hayden R Wright; Collin R Warrick; Martin A Sticht; Maria Morena; Itziar Bonilla; Sarah A Laredo; Rebecca M Craft; Loren H Parsons; Pedro R Grandes; Cecilia J Hillard; Matthew N Hill; Ryan J McLaughlin
Journal:  Biol Psychiatry       Date:  2018-05-08       Impact factor: 13.382

Review 4.  Renaissance in phytomedicines: promising implications of NGS technologies.

Authors:  Sonal Sharma; Neeta Shrivastava
Journal:  Planta       Date:  2016-03-22       Impact factor: 4.116

Review 5.  Zebrafish: a model for the study of addiction genetics.

Authors:  Eric W Klee; Henning Schneider; Karl J Clark; Margot A Cousin; Jon O Ebbert; W Michael Hooten; Victor M Karpyak; David O Warner; Stephen C Ekker
Journal:  Hum Genet       Date:  2011-12-30       Impact factor: 4.132

Review 6.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Authors:  George W Booz
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

7.  Subacute cannabidiol alters genome-wide DNA methylation in adult mouse hippocampus.

Authors:  Nicole M Wanner; Mathia Colwell; Chelsea Drown; Christopher Faulk
Journal:  Environ Mol Mutagen       Date:  2020-08-10       Impact factor: 3.216

8.  Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Authors:  John Merrick; Brian Lane; Terri Sebree; Tony Yaksh; Carol O'Neill; Stan L Banks
Journal:  Cannabis Cannabinoid Res       Date:  2016-04-01

Review 9.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Authors:  Alline Cristina Campos; Fabricio Araújo Moreira; Felipe Villela Gomes; Elaine Aparecida Del Bel; Francisco Silveira Guimarães
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.